Main Menu Jump to Page

View Complaint
Retainer Agreement
info@rosenlegal.com

Obalon shareholders have an opportunity to recover their investment losses.

Click "Join this Class Action" above.

Attorneys

Obalon Therapeutics, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Obalon Therapeutics, Inc. (NASDAQ: OBLN) from October 5, 2016 through January 23, 2018, inclusive. The lawsuit seeks recovery of investor losses.

If you purchased shares of Obalon between October 5, 2016 and January 23, 2018 and would like to join the action, please click "Join This Class Action" above.

Press Release

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Obalon Therapeutics, Inc. – OBLN

New York, N.Y., February 15, 2018. Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Obalon Therapeutics, Inc. (NASDAQ: OBLN) from October 5, 2016 through January 23, 2018, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Obalon investors under the federal securities laws.

To join the Obalon class action, go to http://rosenlegal.com/cases-1275.html or call Phillip Kim, Esq. or Daniel Sadeh, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or dsadeh@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, during the Class Period defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Obalon recognized revenue in violation of Generally Accepted Accounting Principles; (2) Obalon lacked adequate internal controls over accounting and financial reporting; and (3) as a result, defendants’ statements about Obalon’s business, operations, and prospects were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 16, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1275.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Daniel Sadeh, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or dsadeh@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

-------------------------------

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      Daniel Sadeh, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 34th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      lrosen@rosenlegal.com
      pkim@rosenlegal.com
      dsadeh@rosenlegal.com
      www.rosenlegal.com